Elly Scheermeyer

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Aim We aimed to assess the benefits and safety of low dose growth hormone treatment (GHT, 4.5 mg/m 2 /week) in young children with genetically confirmed Prader-Willi Syndrome (PWS). Methods Data of 20 infants (2-12 months) and 24 toddlers (13-24 months) were collected from the PWS-OZGROW database. The two groups were evaluated for standard deviation scores(More)
  • 1